Day: May 26, 2020

VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) — Golden Predator Mining Corp. (TSX.V:GPY, OTCQX:NTGSF) (the “Company”) announced today that it has closed the sale of its 100% interest in the 3 Aces gold project to Seabridge Gold Corp. for 300,000 Seabridge common shares ($6.67 million valuation as of Friday’s close), contingent future cash payments totaling $2.25 million and a continuing royalty participation in the project by Golden Predator.“This non-dilutive transaction strengthens our balance sheet and allows the Company to focus entirely on our advanced and permitted Brewery Creek Mine. In the past year, we have seen an impressive growth in the gold resource at Brewery Creek as recently defined in the 2019 NI 43-101 technical report. In addition our successful 2019 drill program of 137 step-out and infill holes...

Manufacturing capacity ramping up to fulfill significant backlog of customer ordersTemporary reductions to pay and hours for salaried employees partially easedRecent order patterns reflect significant declines compared to the prior yearLiquidity remains very strong at approximately $774 million as of May 1GRAND RAPIDS, Mich., May 26, 2020 (GLOBE NEWSWIRE) — Steelcase Inc. (NYSE: SCS) announced today it has called back most of its manufacturing workforce from temporary layoffs as government restrictions related to the COVID-19 pandemic are beginning to ease.  All of the company’s manufacturing and distribution locations around the world are open, with some locations in the process of scaling up capacity levels and a few locations continuing to be subject to government restrictions that prevent them from operating at normal capacity. ...

The focuses are to Establish the Tauri-Gum™ Brand in the Canadian Health, Wellness and Retail MarketplaceNEW YORK, NY, May 26, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has executed a Letter of Intent (“LOI”) with Pegasus Medical Holdings, Inc. (“Pegasus”), to enter the Canadian marketplace with its flagship brand: Tauri-Gum™.  Pegasus will concurrently enter into an agreement with ParcelPal Technology, Inc. (“ParcelPal”), a Vancouver, British Columbia based publicly traded company that provides last mile logistics and delivery...

NEW YORK and VIENNA, Austria, May 26, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and present at Jefferies Virtual Healthcare Conference, taking place June 2 – 4, 2020.Presentation: Wednesday, June 3, 2020 at 8:30 a.m. ETThe live audio webcast of the presentation held at Jefferies Virtual Healthcare Conference will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION TO UNITED STATESVANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) — Lundin Gold Inc. (“Lundin Gold” or the “Company”) (TSX: LUG, Nasdaq Stockholm: LUG) has announced today that it has entered into an agreement with BMO Capital Markets (“BMO”), under which BMO has agreed to buy on a bought deal basis 4,150,000 common shares (the “Common Shares”), at a price of C$12.05 per Common Share for gross proceeds of approximately C$50 million (the “Offering”). The Company has granted BMO an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. The offering is expected to close on or about June 11,...

Press releaseSynairgen plc(‘Synairgen’ or the ‘Company’)Update on expanded SG016 trial for patients with COVID-19:Synairgen initiates dosing of SNG001 in home setting to treat patients earlier in the illnessSouthampton, UK – 26 May 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that it has launched an expansion of the SG016 trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients to dose patients in the home setting. The expansion of the trial aims to dose patients earlier in the illness, within three days of symptoms developing.This follows receipt of the necessary approvals to expand the ongoing SG016 trial from the original 100 patients, to include enrolling an additional 120 patients in the home environment, as announced by the Company on 30 April 2020.Richard...

U.S. FDA Grants Emergency Use AuthorizationSTERIS Creates New Decontamination Cycle that Allows Hospitals to Use Their Existing Steam SterilizersDUBLIN, IRELAND, May 26, 2020 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has issued another Emergency Use Authorization (EUA) for respirator decontamination.  The EUA enables healthcare providers to decontaminate surgical N95 respirators by utilizing certain AMSCO Steam Sterilizers that have been upgraded with STERIS’s new “Decon” cycle. This EUA is the second authorization for STERIS to temporarily provide a solution for decontaminating compatible N95 respirators.  The first EUA, announced by STERIS on April 10, 2020, utilizes vaporized hydrogen peroxide to decontaminate respirators.  “It is encouraging...

WATERTOWN, Mass., May 26, 2020 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:30 AM ET.A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company’s website at www.eyepoint.com. The replay will be available for 90 days after the event.About EyePoint PharmaceuticalsEyePoint Pharmaceuticals, Inc. (www.eyepointpharma.com) is a pharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve...

Company Announcement, Insider information  26 May 2020 at 2:00 pm (UTC +3.00).The Board of Directors of BBS-Bioactive Bone Substitutes Plc decided on a subscription rights issue and publishes the prospectus and issue termsNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SINGAPORE, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.Following the company announcement on 20 May 2020, the Board of Directors of BBS-Bioactive Bone Substitutes Plc (“BBS” or the “Company”) has today decided, on the bases of the authorisation of Annual General Meeting on 5 April 2019, to arrange a rights issue totaling approximately EUR 5.5 million (the “Offering”). The Finnish Financial Supervisory Authority has today approved...

Yhtiötiedote, sisäpiiritieto, 26.5.2020 klo 14:00BBS-Bioactive Bone Substitutes Oyj:n hallitus päätti merkintäoikeusannista sekä julkistaa sen ehdot ja esitteenEI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI KOKONAISUUDESSAAN TAI OSITTAIN EIKÄ SUORAAN TAI VÄLILLISESTI YHDYSVALLOISSA, AUSTRALIASSA, KANADASSA, HONGKONGISSA, SINGAPORESSA, JAPANISSA, UUDESSA-SEELANNISSA TAI ETELÄ-AFRIKASSA TAI MISSÄÄN MUUSSA VALTIOSSA, JOSSA LEVITTÄMINEN TAI JULKAISEMINEN OLISI LAINVASTAISTA.Viitaten BBS-Bioactive Bone Substitutes Oyj:n (”BBS” tai ”Yhtiö”) 20.5.2020 julkaistuun yhtiötiedotteeseen Yhtiön hallitus on tänään päättänyt 5.4.2019 pidetyn yhtiökokouksen valtuutuksen perusteella järjestää noin 5,5 miljoonan euron suuruisen merkintäoikeusannin (”Osakeanti”). Finanssivalvonta on tänään hyväksynyt BBS:n Osakeannista laatiman suomenkielisen esitteen.Osakeannissa...